Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.Peer-Reviewed Original ResearchSemi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information
Wei W, Sun Z, da Silveira W, Yu Z, Lawson A, Hardiman G, Kelemen L, Chung D. Semi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information. Statistical Methods In Medical Research 2018, 28: 2137-2149. PMID: 29336210, PMCID: PMC6922004, DOI: 10.1177/0962280217752980.Peer-Reviewed Original ResearchConceptsCancer subgroupsAustralian Ovarian Cancer StudyHigh-grade serous ovarian cancerCancer patient subgroupsSerous ovarian cancerMolecular featuresOvarian Cancer StudyCancer Genome AtlasSurvival outcomesTreatment of cancerCancer patientsPatient subgroupsOvarian cancerPersonalized treatmentCancer progressionGenome AtlasCancer studiesKey molecular featuresSubgroupsCancerClear benefitTreatmentPatientsClinicians